Pancreatic Adenocarcinoma in New Mexico Native Americans: Disparities in Treatment and Survival.
Additional Document Info
In this study, we examined the treatment and outcomes of pancreatic adenocarcinoma in New Mexico Native Americans (NA).A retrospective review of patients treated for pancreatic adenocarcinoma at a university cancer center from 2002-2016 comparing demographic characteristics, disease presentation, treatment, and outcomes among three main ethnic groups in New Mexico.We identified 457 patients: 240 (52.5%) non-Hispanic Whites, 186 (40.7%) Hispanics, and 31 (6.8%) NA. Non-Hispanic Whites (OR 2.41; p=.026) and Hispanics (OR 2.37; p=.032) were more likely to receive or be offered chemotherapy than NA. More NA than non-Hispanic Whites died within one month of diagnosis (25.8% and 7.5%, respectively; p=.004). The NAs demonstrated a 26.2% one-year survival (CI 11.7-43.3), compared with 48.3% in non-Hispanic Whites (CI 40.9-55.2; p=.015).Significant disparities exist in the treatment and outcomes of pancreatic adenocarcinoma in New Mexico NA populations.